Xin Lang Cai Jing·2025-08-28 01:22Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Junshi Biosciences, including stock price movements and trading volumes [1] - On August 27, Junshi Biosciences experienced a stock decline of 3.96% with a trading volume of 1.039 billion yuan, and a net financing buy of -999.91 million yuan [1] - As of August 27, the total margin balance for Junshi Biosciences was 1.287 billion yuan, with a financing balance of 1.280 billion yuan, representing 3.85% of the circulating market value [1] Group 2 - As of June 30, Junshi Biosciences had 31,200 shareholders, an increase of 5.88% from the previous period, while the average circulating shares per person decreased by 5.56% to 24,543 shares [2] - For the first half of 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, and a net profit attributable to shareholders of -413 million yuan, an increase of 36.01% year-on-year [2] - Among the top ten circulating shareholders as of June 30, 2025, Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares, while E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [2]